- Gap between patients waiting for organ transplant and available organ donors
- Rising demand for cost-efficient technologies in drug development processes
- Growth in adoption of 3D bioprinted bone grafts and dental consumables
Monday, 25 July 2016
Research providing in-depth analysis on the 3D Bioprinters Market 2023, Credence Research
The latest Industry information published by Credence Research, Inc. “Global 3D Bioprinters Industry- Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022,” the 3D bioprinters Industrywas valued at USD 562.8 Mn in 2015, and is expected to reach USD 1,942.5 Mn by 2022, expanding at a CAGR of 18.8% from 2016 to 2022.
Browse the full report 3D Bioprinters Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/3d-bioprinters-market
3D bioprinting is the process that allows researchers to generate and assemble cellular layers to form organic tissues. The use of biomaterial cells, proteins or other biological compounds as building block is carried out for fabricating 3D personalized structures or in vitro biological models through additive manufacturing processes. The major factors driving 3D bioprinters Industryare increasing demand for organ transplants, and requirement of cost-efficient technologies in drug development. According to the Organ Procurement and Transplantation Network (OPTN) and the Gift of Life Donor Program, in the U.S., an average of 21 people die every day waiting for an organ transplant, and the wait times can range from four months for a heart to five years for a kidney. The global 3D bioprinters Industryis represented by key technologies namely, syringe based 3D bioprinting, laser based 3D bioprinting, magnetic levitation 3D bioprinting, inkjet based 3D bioprinting and valve-based 3D bioprinting. Among these syringe based 3D bioprinting is the largest segment and is anticipated to maintain its lead during the forecast period 2016 – 2022. Pharmaceuticals segment accounted for a major share of 31.70% in the 3D bioprinting market. Drug development today is increasingly focusing on reducing side effects, improving treatment outcomes and deserting the ‘one-size-fits-all’ approach to medication management.
Sample, Link : http://www.credenceresearch.com/sample-request/57766
Industry Competition Assessment
According to Industryexperts competition in 3D bioprinting Industryis low and barriers are high. Competition is low due to presence of niche opportunities in the healthcare industry and barriers are high because the research is very specialized and requires a significant amount of investment, usually by the government or private donors, while the risks to profitability remain very high. 3D Systems, Inc. and Stratasys Ltd. dominate the 3D printer applications in healthcare market. The other upcoming key players such as Organovo, Inc. and EnvisionTEC, Inc. are expected to be one of the leading players in 3D bioprinting Industryin the near future.
Key Industry Movements
Credence Research is a worldwide Industryresearch and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US